NCT06197438View on ClinicalTrials.gov

Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

April 11, 2024

Study Completion Date

April 1, 2025

Conditions
Gastric Cancer
Interventions
DRUG

Tislelizumab

Tislelizumab will be administered on day 1 of each cycle at 200mg once every 21 days.

DRUG

Oxaliplatin

Oxaliplatin will be administered on day 1 of each cycle at 85mg/m2 once every 14 days.

DRUG

Levo-Leucovorin

Levo-Leucovorin will be administered on day 1 of each cycle at 200 mg/m2 once every 14 days.

DRUG

5-fluorouracil

5-fluorouracil will be administered at 2400 mg/m2 over 46-hour every 14 days.

DRUG

Irinotecan Hydrochloride

Irinotecan will be administered on day 1 of each cycle at 135 mg/m2 once every 14 days.

DRUG

Paclitaxel

Paclitaxel will be administered on day 1 of each cycle at 90 mg/m2 once every 14 days.

All Listed Sponsors
lead

Fujian Cancer Hospital

OTHER_GOV

NCT06197438 - Phase II Study of the Combination of Irinotecan and POF (POFI) and Tislelizumab in Advanced Gastric Cancer | Biotech Hunter | Biotech Hunter